Literature DB >> 7689562

Site-specific interaction of vaccinia virus topoisomerase I with base and sugar moieties in duplex DNA.

S Shuman1, J Turner.   

Abstract

Vaccinia DNA topoisomerase specifically binds and forms a covalent adduct at DNA sites containing a conserved sequence element 5'(C/T)CCTT decreases in the scissile strand. The molecular interactions that contribute to recognition of the CCCTT motif in a synthetic DNA substrate have been examined using modification interference, modification protection, and analog substitution techniques. We report that topoisomerase makes contact with guanine nucleotide bases of the pentamer motif complementary strand (3'GGGAA) within the major groove of the DNA helix and that alteration of the binding surface by chemical modification is deleterious to the interaction. Additional contacts are made with guanine residues located outside the pentamer element. The enzyme is unable to form a covalent adduct with synthetic RNA substrates. Analysis of the cleavage of DNA duplexes containing 2'OMe sugars suggests that the inability of the vaccinia topoisomerase to cleave either an RNA duplex or an RNA:DNA hybrid can be accounted for by the interfering effects of a 2' sugar substituent at two or more sites within the pentamer. Interaction with the sugar at the +2T nucleotide appears to be the most critical, as judged by the effects of single sugar substitutions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689562

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Position-specific effect of ribonucleotides on the cleavage activity of human topoisomerase II.

Authors:  Y Wang; A Thyssen; O Westergaard; A H Andersen
Journal:  Nucleic Acids Res       Date:  2000-12-15       Impact factor: 16.971

2.  Mutational analysis of vaccinia virus topoisomerase identifies residues involved in DNA binding.

Authors:  J Sekiguchi; S Shuman
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

3.  Major groove interactions of vaccinia Topo I provide specificity by optimally positioning the covalent phosphotyrosine linkage.

Authors:  Rajesh Nagarajan; James T Stivers
Journal:  Biochemistry       Date:  2006-05-09       Impact factor: 3.162

4.  Chemical and traditional mutagenesis of vaccinia DNA topoisomerase provides insights to cleavage site recognition and transesterification chemistry.

Authors:  Lyudmila Yakovleva; Shengxi Chen; Sidney M Hecht; Stewart Shuman
Journal:  J Biol Chem       Date:  2008-03-25       Impact factor: 5.157

5.  DNA strand transfer reactions catalyzed by vaccinia topoisomerase: hydrolysis and glycerololysis of the covalent protein-DNA intermediate.

Authors:  B O Petersen; S Shuman
Journal:  Nucleic Acids Res       Date:  1997-06-01       Impact factor: 16.971

6.  Determination of the recognition sequence of Mycobacterium smegmatis topoisomerase I on mycobacterial genomic sequences.

Authors:  D Sikder; V Nagaraja
Journal:  Nucleic Acids Res       Date:  2000-04-15       Impact factor: 16.971

7.  Resolution of Holliday junctions by eukaryotic DNA topoisomerase I.

Authors:  J Sekiguchi; N C Seeman; S Shuman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

8.  Requirements for noncovalent binding of vaccinia topoisomerase I to duplex DNA.

Authors:  J Sekiguchi; S Shuman
Journal:  Nucleic Acids Res       Date:  1994-12-11       Impact factor: 16.971

9.  Chemical mutagenesis of vaccinia DNA topoisomerase lysine 167 provides insights to the catalysis of DNA transesterification.

Authors:  Lyudmila Yakovleva; Stewart Shuman
Journal:  Biochemistry       Date:  2013-01-23       Impact factor: 3.162

10.  Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.

Authors:  Wei-Guo Zhu; Kanur Srinivasan; Zunyan Dai; Wenrui Duan; Lawrence J Druhan; Haiming Ding; Lisa Yee; Miguel A Villalona-Calero; Christoph Plass; Gregory A Otterson
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.